Renal Cancer - Results from #4740

Individualized dosing with axitinib: rationale and practical guidance December 29, 2017

Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma-a multicenter analysis of the German working group "Stereotactic Radiotherapy" December 28, 2017

99mTc-Sestamibi SPECT/CT for the characterization of renal masses: a pictorial guide December 27, 2017

Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial December 26, 2017

Survival outcomes of double- and triple-sequential targeted therapy in patients with metastatic renal cell carcinoma: a retrospective comparison December 25, 2017

Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting December 22, 2017

Laser desorption/ionization MS imaging of cancer kidney tissue on silver nanoparticle-enhanced target December 22, 2017

Incision site metastasis: Adding insult to injury December 22, 2017

Three-dimensional printed model of bilateral Wilms tumor: A useful tool for planning nephron sparing surgery December 22, 2017

Differential diagnosis of the small renal masses: role of the apparent diffusion coefficient of the diffusion-weighted MRI December 22, 2017

Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study December 21, 2017

Outcomes of Patients With Late-Relapse Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Single Institution Experience December 21, 2017

Impact of positive surgical margins on overall survival after partial nephrectomy-A matched comparison based on the National Cancer Database December 21, 2017

Recurrence of renal cell cancer after renal transplantation in a multicenter French cohort December 21, 2017

U.S. FDA Approves CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma December 20, 2017

Sutent® (sunitinib malate) is FDA Approved as the First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma December 20, 2017

FDA Approves Adjuvant Treatment for Adult Patients at a High Risk of Kidney Cancer Returning after Nephrectomy December 20, 2017

Hospital Volume and Outcomes of Robot-Assisted Partial Nephrectomy December 20, 2017

Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis December 20, 2017

Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study December 20, 2017

Page 238 of 456